by April Breyer Menon | Feb 28, 2026
Download PDF *Adalimumab Challenged Claim Types in IPR and Litigation: Claims include those challenged in litigations and IPRs. Claims are counted in each litigation and IPR, so claims from the same patent challenged in multiple...
by April Breyer Menon | Feb 28, 2026
Download PDF *Rituximab Challenged Claim Types in IPR and Litigation: Claims include those challenged in litigations and IPRs. Claims are counted in each litigation and IPR, so claims from the same patent challenged in multiple...
by April Breyer Menon | Feb 28, 2026
Download PDF *Insulin Glargine Challenged Claim Types in IPR and Litigation: Claims include those challenged in litigations and IPRs. Claims are counted in each litigation and IPR, so claims from the same patent challenged in multiple litigations/IPRs...
by April Breyer Menon | Feb 27, 2026
On February 24, 2026, the Court in Case No. 1:23-cv-10861 (D. Mass.) granted Amgen’s motions for summary judgment of invalidity of the claims of OssiFi-Mab’s (“OMAB”) U.S. Patent Nos. 8,877,196 (“the ’196 patent), 11,608,373 (“the ’373 patent”), and 11,807,681 (“the...
by April Breyer Menon | Feb 27, 2026
On February 20, 2026, in Case No. 24-1408, the CAFC reversed and remanded the district court’s summary judgment decision (Case No. 1:20-cv-01226 (D. Del.)) finding the claims of REGENXBIO’s U.S. Patent No. 10,526,617 (“the ’617 patent”) invalid under 35 U.S.C. § 101...
